INTERIM RESULTS FROM A SINGLE-ARM MULTICENTER PHASE II TRIAL OF CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)

被引：2
|
作者：
Packiam, Vignesh T.
Barocas, Daniel A.
Chamie, Karim
Davis, Ronald L., III
Kader, A. Karim
Lamm, Donald L.
Curran, Dominic
Yeung, Alex W.
Steinberg, Gary D.
机构：
来源：
JOURNAL OF UROLOGY | 2017年 / 197卷 / 04期
关键词：
D O I：
10.1016/j.juro.2017.03.039
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PNFLBA-13
引用
收藏
页码：E915 / E916
页数：2
相关论文
共 50 条
  • [21] CORE1: Phase 2 single arm study of CG0070 combined with pembrolizumab in patients with non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin (BCG)
    Li, R.
    Steinberg, G. S.
    Uchio, E. U.
    Lamm, D. L.
    Shah, P. S.
    Kamat, A. K.
    Trinity, B.
    Packiam, V.
    Chisamore, M. C.
    Mcadory, J.
    Grandi, P.
    Hnat, N.
    Burke, J.
    EUROPEAN UROLOGY, 2023, 83 : S603 - S603
  • [22] Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
    Boorjian, Stephen A.
    Alemozaffar, Mehrdad
    Konety, Badrinath R.
    Shore, Neal D.
    Gomella, Leonard G.
    Kamat, Ashish M.
    Bivalacqua, Trinity J.
    Montgomery, Jeffrey S.
    Lerner, Seth P.
    Busby, Joseph E.
    Poch, Michael
    Crispen, Paul L.
    Steinberg, Gary D.
    Schuckman, Anne K.
    Downs, Tracy M.
    Svatek, Robert S.
    Mashni, Joseph, Jr.
    Lane, Brian R.
    Guzzo, Thomas J.
    Bratslavsky, Gennady
    Karsh, Lawrence I.
    Woods, Michael E.
    Brown, Gordon
    Canter, Daniel
    Luchey, Adam
    Lotan, Yair
    Krupski, Tracey
    Inman, Brant A.
    Williams, Michael B.
    Cookson, Michael S.
    Keegan, Kirk A.
    Andriole, Gerald L., Jr.
    Sankin, Alexander I.
    Boyd, Alan
    O'Donnell, Michael A.
    Sawutz, David
    Philipson, Richard
    Coll, Ruth
    Narayan, Vikram M.
    Treasure, F. Peter
    Yla-Herttuala, Seppo
    Parker, Nigel R.
    Dinney, Colin P. N.
    LANCET ONCOLOGY, 2021, 22 (01): : 107 - 117
  • [23] Updated results of a phase I/II trial of intravesical CG0070 in patients with superficial bladder cancer after BCG failure
    Friedlander, Terence W.
    Weinberg, Vivian K.
    Yeung, Alex
    Burke, James
    Lamm, Donald L.
    McKiernan, James M.
    Nemunaitis, John J.
    Stephenson, Joe
    Small, Eric Jay
    Fong, Lawrence
    Meng, Maxwell V.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [24] S1605: Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer
    Singh, Parminder
    Catherine, Tangen
    Lerner, Seth P.
    McConkey, David
    Plets, Melissa
    Lucia, M. Scott
    Woods, Michael
    Bivalacqua, Trinity
    Kassouf, Wassim
    Bangs, Richard Carlton
    Thompson, Ian Murchie
    Black, Peter C.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] Phase 1 study of multi-dose administration of intravesical CG0070 in patients with non-muscle invasive bladder cancer (NMIBC)
    McKiernan, James M.
    Lamm, Donald L.
    Meng, Maxwell V.
    Nemunaitis, John J.
    Arseneau, James C.
    Stephenson, Joe
    Burke, James M.
    Aimi, Junko
    Maslyar, Daniel J.
    JOURNAL OF UROLOGY, 2008, 179 (04): : 616 - 616
  • [26] Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial
    Grabbert, Markus
    Seiler, Roland
    Gratzke, Christian
    EUROPEAN UROLOGY, 2021, 80 (01) : 114 - 114
  • [27] Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial
    Soria, Francesco
    Gontero, Paolo
    EUROPEAN UROLOGY, 2021, 79 (06) : 891 - 892
  • [28] Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Open-Label, Repeat-Dose Clinical Trial
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2021, 206 (03): : 770 - 771
  • [29] Phase II trial of intravesical camrelizumab in BCG-unresponsive high-risk non-muscle invasive bladder cancer
    Shen, Yijun
    Peng, Liangju
    Xu, Peihang
    Wang, Yanhao
    Wang, Xiang
    Yao Xudong
    Liu, Yushan
    Ye, Ding-Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Intravesical gemcitabine as bladder-preserving treatment for BCG unresponsive non-muscle-invasive bladder cancer. Results from a single-arm, open-label study
    Hurle, Rodolfo
    Casale, Paolo
    Morenghi, Emanuela
    Saita, Alberto
    Buffi, Nicolomaria
    Lughezzani, Giovanni
    Colombo, Piergiuseppe
    Contieri, Roberto
    Frego, Nicola
    Guazzoni, Giorgio
    Lazzeri, Massimo
    BJUI COMPASS, 2020, 1 (04): : 126 - 132
12345